| Size | Price | |
|---|---|---|
| Other Sizes |
| ln Vitro |
Gingival fibroblasts are more likely to detach and differentiate when exposed to Nisin Z (10 μg/mL, 24 h) [2]. For 24 hours, nisin Z (25–75 μg/mL) prevents C from adhering. gingival cells to albicans[2]. Nisin Z (500 and 1000 μg/mL, 24 hours) prevents C from forming germ tubes. albicans [3]. Nisin Z (10-100 μg/mL, 12 h) inhibits LPS-induced activation of ERK1/2 and p38 MAPK signaling pathways in MCF10A cells [4]. Nisin Z (100 μg/mL, 12 h) lowers LPS-induced production of pro-inflammatory cytokines (i.e., IL-6, TNF-α, IL-1β) in MCF10A cells [4].
|
|---|---|
| ln Vivo |
In an LPS-induced mouse mastitis model, nisin Z (1, 5 and 10 mg/kg, ip) inhibits pathological damage [4].
|
| Cell Assay |
Cell Viability Assay[3]
Cell Types: C. albicans Tested Concentrations: 100, 500, 1000 μg/mL Incubation Duration: 24, 48, and 72 h Experimental Results: decreased C. albicans growth. Western Blot Analysis[4] Cell Types: LPS-induced MCF10A cells Tested Concentrations: 10-100 μg/mL Incubation Duration: 12 h Experimental Results: Inhibited the phosphorylation of p38 and and ERK1/ 2. |
| Animal Protocol |
Animal/Disease Models: Mastitis mouse model[4]
Doses: 1, 5, and 10 mg/kg Route of Administration: ip, one hour before treatment of LPS. Experimental Results: diminished inflammatory cell infiltration. demonstrated a reduction in inflammatory cytokine levels. |
| References |
[1]. Webber JL, et al. Incorporation and antimicrobial activity of nisin Z within carrageenan/chitosan multilayers. Sci Rep. 2021 Jan 18;11(1):1690.
[2]. Akerey B, et al. In vitro efficacy of nisin Z against Candida albicans adhesion and transition following contact with normal human gingival cells. J Appl Microbiol. 2009 Oct;107(4):1298-307. [3]. Le Lay C, et al. Nisin Z inhibits the growth of Candida albicans and its transition from blastospore to hyphal form. J Appl Microbiol. 2008 Nov;105(5):1630-9. [4]. Huang F, et al. Nisin Z attenuates lipopolysaccharide-induced mastitis by inhibiting the ERK1/2 and p38 mitogen-activated protein kinase signaling pathways. J Dairy Sci. 2022 Apr;105(4):3530-3543. |
| Molecular Formula |
C141H229N41O38S7
|
|---|---|
| Molecular Weight |
3331.05
|
| CAS # |
137061-46-2
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
O=C1C(C(SCC(NC(=O)CNC(=O)C2CCCN12)C(=O)NC(CCCCN)C(=O)NC1C(NCC(NC(C(NC(C(=O)NC(CCSC)C(=O)NCC(=O)NC(C(=O)NC(CC(=O)N)C(=O)NC(CCSC)C(=O)NC(CCCCN)C(=O)NC2C(NC(C(NC3C(SCC(C(=O)NC(CO)C(=O)NC(C(C)CC)C(=O)NC(C(=O)NC(C(C)C)C(=O)NC(=C)C(=O)NC(C(=O)O)CCCCN)CC4N=CNC=4)NC(=O)C(CC(=O)N)NC(=O)C(NC3=O)CSC2C)C)=O)C)=O)CSC1C)CC(C)C)=O)C)=O)=O)C)NC(C1CSCC(C(NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CC(C)C)C(=O)N1)=O)NC(=O)C(=CC)NC(=O)C(N)C(C)CC)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~10 mg/mL (~3.00 mM)
DMSO : ~2 mg/mL (~0.60 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.2 mg/mL (0.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 2.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 2: ≥ 0.2 mg/mL (0.06 mM) (saturation unknown) in 10% DMSO + 90% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.14 mg/mL (0.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3002 mL | 1.5010 mL | 3.0021 mL | |
| 5 mM | 0.0600 mL | 0.3002 mL | 0.6004 mL | |
| 10 mM | 0.0300 mL | 0.1501 mL | 0.3002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
